Suven Life Sciences slides on weak quarterly show

News Flash

ACQUISITION TO BE INCREMENTALLY POSITIVE FOR RELIANCE INDUSTRIES
UNLIKELY TO SEE SHARP CORRECTION IN MARKETS, NOT POSITIVE ON REALTY SPACE
IMPORTS & EXPORTS TO BE USED TO KEEP SUGAR PRICES RANGE BOUND
NEED A LONGER TERM PRICE OBJECTIVE FOR CROPS LIKE SUGARCANE
RIL TO GET CHEAP FEEDSTOCK VIA LYONDELL BASELL ACQUISITION
RIL TO GET CHEAP FEEDSTOCK VIA LYONDELLBASELL ACQUISITION
RIL IN A MUCH STRONGER POSITION THAN COMPETITORS FOR THIS ACQUISITION
RIL WILL GET CHEAP FEEDSTOCK BY THIS ACQUISITION
MARKET DIVIDED OVER FED'S DIRECTION IN TERMS OF INTEREST RATES
INDIAN ECONOMY LOOKING A LOT BETTER THAN OTHERS
HANG SENG UP 0.56%; NIKKEI DOWN 0.54%; KOSPI DOWN 0.17%
ACQUISITION TO GIVE RIL BARGAINING POWER IN PROCUREMENT & SALES
JAPANESE MARKET SHUT TODAY ON ACCOUNT OF THANKS GIVING
RIL'S INTEREST DOESN'T COMMIT MUCH NOW BUT GETS RIL A FOOT IN THE DOOR
NYMEX CRUDE AT $78/BBL ON TENSIONS BETWEEN IRAN & WESTERN NATIONS
HDIL LOSES 1.5%, ADDS 9 LAKH SHARES IN OPEN INTEREST
NTPC GAINS 1.1%, ADDS 12.7 LAKH SHARES IN OPEN INTEREST
BHARTI LOSES 1.5%, ADDS 14.7 LAKH SHARES IN OPEN INTEREST
DENA BANK GAINS 13.7%, ADDS 45.9 LAKH SHARES IN OPEN INTEREST
NIFTY NOVEMBER FUTURES SHED 14.5 LAKH SHARES IN OPEN INTEREST
NIFTY PREMIUM OF 13.8 POINTS VS A DISCOUNT OF 2.4 POINTS ON THURSDAY
NIFTY ROLLOVERS STOOD AT 26.7%
NIFTY NOVEMBER PUT-CALL RATIO AT 1.83 VS 1.58 ON THURSDAY
FOREIGN FUNDS NET SELL RS.463.89 CR IN EQUITIES ON NOVEMBER 20 (PROV)
MUTUAL FUNDS NET SELL RS.176.7 CR IN EQUITIES ON NOVEMBER 19
DII'S NET BUY RS.18.46 CR IN EQUITIES ON NOVEMBER 20 (PROV)
TO ENTER INTO CUSTOMIZED MOTOR CYCLE BIZ VIA PRO-BIKING SHOWROOMS
TO EXPAND PANTNAGAR CAPACITY TO 70,000 UNITS IN NEXT FEW MONTHS
AKER IS A NORWEGIAN SERVICE PROVIDER CO FOR OIL AND GAS OPERATIONS
AKER SOLUTIONS TO PROVIDE SUPPORT SERVICES IN KG BASIN

Updated: 03/11/2009 | 12:00 AM IST

Hot pursuit

Capital Market

Tuesday, November 03, 2009 (New Delhi)

Blog

Comments:

Read (0)

Post

Rate the story

Meanwhile, the BSE Sensex was down 41.87 points, or 0.26%, to 15,854.41.

On BSE, 27,721 shares were traded in the counter as against an average daily volume of 2.85 lakh shares in the past one quarter.

The stock hit a high of Rs 26.80 and a low of Rs 25.05 so far during the day. The stock had hit a 52-week high of Rs 37.40 on 27 August 2009 and a 52-week low of Rs 9.40 on 16 March 2009.

The small-cap stock had underperformed the market over the past one month till 30 October 2009, falling 12.89% as compared to the Sensex's 7.18% fall. It had outperformed the market in the past one quarter, gaining 12.61% as compared to the Sensex's return of 3.30%.

The company's equity capital is Rs 11.59 crore. Face value per share is Rs 1.

The current price of Rs 25.60 discounts the company's Q2 September 2009 annualized EPS of Rs 0.87, by a PE multiple of 29.43.

Suven Life Sciences' net sales dropped 12.3% to Rs 33.19 crore in Q2 September 2009 over Q2 September 2008. The company announced the results on Saturday, 31 October 2009.

Suven Life Sciences had on 14 October 2009 secured product patents for SUVN-502, which is in development stage, in several countries including India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe. The patent in all these countries is valid till June 2023.

In April 2009, Suven Life Sciences completed its phase I trials for SUVN-502. It is a lead compound intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, Schizophrenia.

The company is planning to initiate the clinical Phase-II proof of concept studies during 2010. The company may launch SUVN-502 in later 2013 or in early 2014.

Early September 2009, Suven Life Sciences received its first milestone payment from Eli Lilly and Company, US, with their drug discovery collaboration achieving a positive outcome.

Suven Life Sciences is engaged in design, manufacture and the supply of bulk active, drug intermediates and fine chemicals to the life science industry. The company mainly operates in the USA, Europe, Asia and India.

Powered by Capital Market - Live News